Stawski Robert, Stec-Martyna Emilia, Chmielecki Adam, Nowak Dariusz, Perdas Ewelina
Department of Clinical Physiology, Medical University of Lodz, 92-215 Lodz, Poland.
Central Scientific Laboratory, Medical University of Lodz, 6/8 Mazowiecka St., 92-215 Lodz, Poland.
Biology (Basel). 2021 Sep 13;10(9):906. doi: 10.3390/biology10090906.
We aimed to summarize the current knowledge about the trends in cfDNA application based on the analysis of clinical trials registered until April 2021. International Clinical Trials Registry Platform (ICTRP) and Clinicaltrials.gov were searched with the keywords: "cf-DNA"; "Circulating DNA"; "Deoxyribonucleic Acid"; and "Cell-Free Deoxyribonucleic Acid". Of 605 clinical trials, we excluded 237 trials, and 368 remaining ones were subject to further analysis. The subject, number of participants, and study design were analyzed. Our scoping review revealed three main trends: oncology (n = 255), non-invasive prenatal diagnostic (n = 48), and organ transplantation (n = 41), and many (n = 22) less common such as sepsis, sport, or autoimmune diseases in 368 clinical trials. Clinical trials are translating theory into clinical care. However, the diagnostic value of cfDNA remains controversial, and diagnostic accuracy still needs to be evaluated. Thus, further studies are necessary until cfDNA turns into a standard in clinical practice.
我们旨在通过分析截至2021年4月登记的临床试验,总结当前关于cfDNA应用趋势的知识。使用关键词“cf-DNA”、“循环DNA”、“脱氧核糖核酸”和“游离脱氧核糖核酸”检索国际临床试验注册平台(ICTRP)和Clinicaltrials.gov。在605项临床试验中,我们排除了237项试验,其余368项试验进行进一步分析。对研究对象、参与者数量和研究设计进行了分析。我们的范围综述揭示了三个主要趋势:肿瘤学(n = 255)、无创产前诊断(n = 48)和器官移植(n = 41),以及368项临床试验中许多(n = 22)不太常见的领域,如败血症、运动或自身免疫性疾病。临床试验正在将理论转化为临床护理。然而,cfDNA的诊断价值仍存在争议,诊断准确性仍需评估。因此,在cfDNA成为临床实践标准之前,有必要进行进一步研究。